Want to see IRD full AI Analyst Report?

Opus Genetics (IRD) Price & Analysis

1,317 Followers

IRD Stock Chart & Stats

$3.08

$0.16(5.48%)

At close: Jul 24 4:00 PM EDT

$3.08

$0.16(5.48%)

Day’s Range― - ―

52-Week Range$1.12 - $5.81

Previous CloseN/A

Volume1.09M

Average Volume (3M)1.08M

Market Cap

$336.94M

Enterprise Value$405.18

Total Cash (Recent Filing)$88.81M

Total Debt (Recent Filing)$34.93M

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Nov 17, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding83,195,820

10 Day Avg. Volume943,049

30 Day Avg. Volume1,081,647

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)81.49

Price to Sales (P/S)88.10

P/FCF Ratio-35.48

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$11.08

Price Target Upside259.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-1.05

Revenue Forecast (FY)$13.36M

Bulls Say, Bears Say

Bulls Say

Broad IRD Gene Therapy PipelineA five-program portfolio diversifies development risk across inherited retinal diseases and creates several opportunities for clinical progress, data readouts and eventual product commercialization rather than relying on a single candidate.

Clinical Development ProgressProgression toward pivotal testing and additional clinical starts can strengthen the company’s development platform, generate validation for its technology and create multiple medium-term milestones that may support future partnering or commercialization.

Rare Disease PositioningTargeting genetically defined rare diseases can support focused trial recruitment, specialized regulatory pathways and potentially less crowded markets. This positioning may improve development efficiency and strengthen long-term commercial differentiation.

Bears Say

Severe And Unstable LossesExtremely large operating and net losses show that the current business has not reached economic scale. Sustained losses could limit internal investment capacity and require continued financing before pipeline programs can generate meaningful revenue.

Negative Equity And Rising DebtThe shift from positive equity and no debt during 2023–2025 to negative equity with meaningful borrowings weakens financial flexibility. It may constrain future financing options and increase the consequences of further development delays.

Persistent Cash BurnHeavy and recurring cash consumption indicates that operations and clinical development depend on external capital. Continued burn raises funding and dilution risk, especially if trials take longer or require more spending than planned.

Opus Genetics News

Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed

Longeveron (LGVN) announced that the company has appointed Nirav Jhaveri to the company’s executive leadership team in the...

4d ago

IRD

LGVN

Opus Genetics price target lowered to $9 from $10 at RBC Capital

RBC Capital lowered the firm’s price target on Opus Genetics (IRD) to $9 from $10 and keeps an...

16d ago

IRD

Opus Genetics files $300M mixed securities shelf

06:23 EDT Opus Genetics (IRD) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

16d ago

IRD

Opus Genetics reports Q2 EPS (14c), consensus (16c)

Reports Q2 revenue $755,000, consensus $2.57M. “With a focus on execution, we are rapidly advancing five gene therapy...

17d ago

IRD

Opus Genetics enrolls last patient in OPGx-LCA5 trial

Opus Genetics (IRD) announced that the last patient has been enrolled in its registrational Phase 3 clinical trial...

20d ago

IRD

Opus Genetics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Opus Genetics (IRD) with a Buy rating without a price target The company’s...

25d ago

IRD

Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data

Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from...

13d ago

IRD

Opus Genetics Earns Buy Rating as Advancing Gene Therapy Pipeline and De-Risked LCA5 Program Support Unchanged $10 Price Target

Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Francois Brisebois from...

16d ago

IRD

Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028

TD Cowen analyst Ritu Baral has maintained their bullish stance on IRD stock, giving a Buy rating yesterday....

16d ago

IRD

IRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Opus Genetics, Inc. (IRD) is scheduled to report 2nd quarter earnings on 08/07/2026. Regarding Q2 estimates, Wall Street...

18d ago

IRD

Opus Genetics: Advancing Gene Therapy Pipeline and Key 2026 Catalyst Support Buy Rating; $12 Price Target Reiterated

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Opus Genetics. The associated price target remains...

19d ago

IRD

Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock

Insiders have been trading these 5 stocks: (($IRD)), (($CYTK)), (($ACI)), (($WFRD)) and (($PAYS)). Here is a breakdown of...

22d ago

ACI

IRD

CarMax, MPLX, Opus, BJ’s, CoStar Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($KMX) ), ( ($MPLX) ), ( ($IRD) ), ( ($BJ)...

22d ago

IRD

Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged

Wedbush analyst Yun Zhong maintained a Buy rating on Opus Genetics today and set a price target of...

2M ago

IRD

IRD FAQ

What was Opus Genetics, Inc.’s price range in the past 12 months?

Opus Genetics, Inc. lowest stock price was $1.12 and its highest was $5.81 in the past 12 months.

What is Opus Genetics, Inc.’s market cap?

Opus Genetics, Inc.’s market cap is $336.94M.

When is Opus Genetics, Inc.’s upcoming earnings report date?

Opus Genetics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 86 days.

How were Opus Genetics, Inc.’s earnings last quarter?

Opus Genetics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.157 by $0.017.

Is Opus Genetics, Inc. overvalued?

According to Wall Street analysts Opus Genetics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Opus Genetics, Inc. pay dividends?

Opus Genetics, Inc. does not currently pay dividends.

What is Opus Genetics, Inc.’s EPS estimate?

Opus Genetics, Inc.’s EPS estimate is -0.15.

How many shares outstanding does Opus Genetics, Inc. have?

Opus Genetics, Inc. has 83,195,820 shares outstanding.

What happened to Opus Genetics, Inc.’s price movement after its last earnings report?

Opus Genetics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.157. Following the earnings report the stock price went down -1.587%.

Which hedge fund is a major shareholder of Opus Genetics, Inc.?

Currently, no hedge funds are holding shares in IRD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Opus Genetics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

140.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Opus Genetics (IRD) Earnings & Revenues

Historic Earnings Reports

IRD Stock 12 Month Forecast

Average Price Target

$11.08

▲(259.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.083333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.71,4.655384615384615,5.600769230769231,6.546153846153846,7.491538461538461,8.436923076923076,9.382307692307691,10.327692307692306,11.273076923076921,12.218461538461536,13.163846153846151,14.109230769230766,15.054615384615385,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.71,4.277179487179487,4.844358974358975,5.411538461538461,5.978717948717948,6.545897435897436,7.113076923076923,7.68025641025641,8.247435897435897,8.814615384615385,9.381794871794872,9.94897435897436,10.516153846153845,{"y":11.083333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.71,4.04,4.37,4.7,5.03,5.36,5.6899999999999995,6.02,6.35,6.68,7.01,7.34,7.67,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >